Reprint
Recent Advances and Clinical Outcomes of Kidney Transplantation
Edited by
September 2020
342 pages
- ISBN978-3-03936-364-3 (Hardback)
- ISBN978-3-03936-365-0 (PDF)
This book is a reprint of the Special Issue Recent Advances and Clinical Outcomes of Kidney Transplantation that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
Advances in immunosuppression and kidney transplant techniques have led to significant improvements in the short-term survival of the renal allograft. Long-term graft survival, however, has relatively lagged behind and has now become one of the main problems in kidney transplantation. In this Special Issue, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored.
Format
- Hardback
License
© 2020 by the authors; CC BY-NC-ND license
Keywords
malondialdehyde; oxidative stress; new-onset diabetes; renal transplantation; BK virus; BK virus nephropathy; kidney allograft; transplantation; Alport syndrome; children; autosomal dominant polycystic kidney disease; epidemiology; hospitalization; kidney transplantation; subarachnoid hemorrhage; malignancy; post-transplant malignancy; renal cell carcinoma; meta-analysis; kidney transplantation; transplantation; systematic reviews; kidney transplantation; tacrolimus; C/D-ratio; pharmacokinetics; kidney transplantation; opportunistic infection; allograft survival; BK virus nephropathy; kidney transplantation; urological complications; ureteric stent; urinary tract infection; timing of removal; living donor; kidney transplantation; ethnicity; age; obesity; genetic relationship donor/recipient; atypical hemolytic uremic syndrome; eculizumab; kidney transplantation; renal transplantation; meta-analysis; kidney transplantation; glucose intolerance; insulin secretion; insulin resistance; oral glucose tolerance test; healthy subject; hyperchloremia; kidney graft dysfunction; living donor kidney transplantation; Uropathogenic E. coli; UPEC; phylogeny; genomics; antibiotic resistance; virulence traits; kidney transplantation; night-time renal transplantation; graft survival; patient survival/outcome; surgical complications; kidney transplantation; acute rejection; lymphocyte; CD45RC; kidney transplantation; Belatacept; cardiovascular high risk; outcome; machine perfusion; organ preservation; temperature; hypothermic; normothermic; transplant; proton-pump inhibitors; iron; iron deficiency; renal transplantation; polyomavirus; BKV; kidney; glomerulus; BKVAN; nephropathy; transplantation; fluid management; kidney transplantation; delayed graft function; goal-directed fluid therapy; calcineurin inhibitor nephrotoxcity; tacrolimus; C/D ratio; tacrolimus metabolism; kidney transplantation; ADPKD; native nephrectomy; kidney transplantation; patient outcome; perioperative complications; epidermal growth factor; creatinine; graft failure; renal transplantation.; new onset diabetes after renal transplantation; single nucleotide polymorphisms; renal transplantation; n/a; kidney transplantation; urinary biomarkers; α-GST; π-GST; acute rejection; delayed graft function; nephrotoxicity; urinary excretion of N1-methylnicotinamide; kidney transplantation; mortality; niacin status; dietary intake; tryptophan; vitamin B3; Kidney transplant; vitamin C; cancer mortality; oxidative stress.; mycophenolic acid; immunosuppression; plasmapheresis; kidney transplantation; oxalate; hyperoxaluria; kidney transplant recipients; graft failure; post-transplantation diabetes mellitus; all-cause mortality; cardiovascular mortality; infectious mortality; proton-pump inhibitors; magnesium; hypomagnesaemia; kidney transplantation; malignancy; cancer; kidney transplant; immunosuppression; graft failure; survival; living kidney donation; living-donor kidney transplantation; beliefs; inequity; ischemia reperfusion injury; kidney transplantation; delayed graft function; innate immune system; adaptive immune system; apoptosis; necrosis; hypoxic inducible factor; endothelial dysfunction; proton pump inhibitor; kidney transplantation; transplant rejection; GFR; insulin-like growth factor 1; growth hormone; muscle mass; patient survival; physical activity; renal transplant recipients; kidney transplant (KT); donor-specific antibodies (DSA); C3d-binding assay; antibody-mediated rejection (AMR); arsenic; diet; fish consumption; oxidative stress; kidney transplantation; graft failure; physical activity; renal transplant recipients; transplantation; post-transplant diabetes mellitus; cardiovascular mortality; mortality; N1-methyl-2-pyridone-5-carboxamide; N1-methylnicotinamide; urinary excretion; renal transplantation; kidney function; biomarker; niacin status; tryptophan; vitamin B3; branched chain amino acids; post-transplant diabetes mellitus; biomarker; renal transplant recipients; posttransplant diarrhea; methanogenesis; Methanosphaera stadtmanae; mucins; sulfate-reducing bacteria; acute humoral rejection; first-line therapy; outcomes; proteasome inhibitor; kidney transplantation; renal transplantation; kidney transplant; renal transplant; transplant recipients; transplantation; tacrolimus; calcineurin inhibitors; FK506; transplantation; kidney transplantation; immunosuppression; pharmacokinetic; C/D ratio; fast tacrolimus metabolizers